Question 1

What is the catalog number for CD68 Human Gene Knockout Kit (CRISPR)?

Accepted Answer

The catalog number for CD68 Human Gene Knockout Kit (CRISPR) is KN400392.

Question 2

What sizes are available for CD68 Human Gene Knockout Kit (CRISPR)?

Accepted Answer

CD68 Human Gene Knockout Kit (CRISPR) is available in the following size(s): 1 Kit.

Question 3

Is CD68 Human Gene Knockout Kit (CRISPR) in stock?

Accepted Answer

CD68 Human Gene Knockout Kit (CRISPR) is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Where can I find the safety data sheet (SDS/MSDS) for CD68 Human Gene Knockout Kit (CRISPR)?

Accepted Answer

The safety data sheet for CD68 Human Gene Knockout Kit (CRISPR) is available here: https://cdn.origene.com/sds/kn400392.pdf.

Question 5

What is CD68 Human Gene Knockout Kit (CRISPR) used for?

Accepted Answer

CD68 - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated.

Question 6

Do you offer custom or private-label production of this type of product?

Accepted Answer

Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.

Question 7

What is the immunogen used to generate this antibody?

Accepted Answer

Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.

Question 8

What is the recommended positive control for this assay?

Accepted Answer

A recommended positive control, where one is specified by the manufacturer, is listed on the datasheet or in the assay protocol.

CD68 Human Gene Knockout Kit (CRISPR)

Product Specifications

UniProt

Gene Location

Symbol

Frequently Asked Questions

Explore Other Products

Thiotriazinone

Diclofenac Levomenthol Ester

TYRP1 (Tyrosinase Related Protein 1) (TA99), CF594 conjugate, 0.1mg/mL

Human ZNF404 activation kit by CRISPRa

Human ARL11 activation kit by CRISPRa

PE Anti-Human CD29 Antibody[TS2/16.2.1]